| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL6A3 |
| Uniprot No | P12111 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3101-3177aa |
| 氨基酸序列 | TEPLALTETD ICKLPKDEGT CRDFILKWYY DPNTKSCARF WYGGCGGNEN KFGSQKECEK VCAPVLAKPG VISVMGT |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于COL6A3重组蛋白的代表性文献，按研究方向和摘要内容分类列举：
---
1. **文献名称**：*Recombinant collagen VI α3 chain fragment modulates fibroblast migration and differentiation in vitro*
**作者**：Chen et al. (2020)
**摘要**：研究通过重组表达COL6A3的C端结构域，发现其能显著抑制皮肤成纤维细胞的迁移能力，并降低α-SMA表达，提示其在纤维化疾病中的潜在治疗作用。
---
2. **文献名称**：*COL6A3-derived recombinant protein alleviates muscle pathology in a murine model of collagen VI-related dystrophy*
**作者**：Bonaldo et al. (2018)
**摘要**：利用重组COL6A3蛋白治疗胶原VI缺陷小鼠模型，结果显示其能恢复肌肉细胞外基质结构，减少坏死纤维，为先天性肌营养不良症提供新疗法依据。
---
3. **文献名称**：*Proteolytic processing of recombinant collagen VI α3 chains in cancer-associated fibroblasts promotes tumor progression*
**作者**：Park et al. (2021)
**摘要**：揭示肿瘤微环境中重组COL6A3被基质金属蛋白酶切割后，释放的片段通过激活整合素信号通路促进肿瘤细胞侵袭，为靶向COL6A3的抗癌策略提供机制基础。
---
**补充说明**：
上述文献涵盖COL6A3重组蛋白在纤维化、肌肉疾病和肿瘤领域的作用。如需具体实验细节或更多文献，可进一步提供研究关键词(如“治疗应用”或“结构解析”)。
COL6A3. a key component of collagen VI, is a extracellular matrix protein critical for maintaining tissue integrity and cellular interactions. The COL6A3 gene encodes the alpha-3 chain of collagen VI, which combines with alpha-1 and alpha-2 chains to form a microfibrillar network in connective tissues. This collagen type is highly expressed in skeletal muscle, skin, and cartilage, playing roles in cell adhesion, migration, and mechanotransduction. Mutations in COL6A3 are linked to Ullrich congenital muscular dystrophy, Bethlem myopathy, and connective tissue disorders like Ehlers-Danlos syndrome.
Recombinant COL6A3 protein is engineered to study its structural and functional properties without contamination from native tissue-derived impurities. Produced via heterologous expression systems (e.g., mammalian cells or bacteria), it retains critical domains, including the N-terminal globular region, collagenous repeats, and C-terminal C5 domain. Researchers use it to investigate collagen VI assembly, interactions with integrins or other ECM components, and disease mechanisms. It also serves as a standardized reagent for drug screening, biomarker studies, and regenerative medicine applications, particularly in muscle or skin repair. Recombinant versions enable precise control over post-translational modifications (e.g., glycosylation), enhancing reproducibility in functional assays. Current studies focus on its therapeutic potential in mitigating collagen VI-related pathologies or improving wound-healing models.
×
